Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Thursday, October 6, 2022
In the tumor microenvironment, the generation of immunosuppressive adenosine leads to the overexpression of the ectoenzyme CD73 and results in a poor prognosis for patients with triple-negative breast cancer. The results of the phase II SYNERGY trial, presented during the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA17), explored whether blocking CD73 with oleclumab enhanced the antitumor response to the combination of anti-PD-L1 with chemotherapy in this patient population. However, Laurence Buisseret, MD, PhD, of the Jules Bordet Institute, Brussels, and colleagues found that the addition of oleclumab to durvalumab did not increase the clinical benefit rate at week 24 in first-line therapy.
The study authors randomly selected 127 women with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer to receive carboplatin and paclitaxel plus durvalumab with oleclumab (n = 83) or without oleclumab (n = 84). The primary endpoint was the clinical benefit rate at week 24. In June 2021, study recruitment was stopped due to futility.
After a median follow-up of 13.2 months, patients treated with oleclumab had a clinical benefit rate of 42.9% versus 43.3% in patients treated without oleclumab. No significant difference was reported according to PD-L1 or CD73 status. The progression-free survival results were comparable between patients treated with or without oleclumab (6 months vs. 7.7 months; P = .89). No significant differences in safety profiles between the two groups were reported. When the study was presented, nine patients in each treatment arm were still under immunotherapy maintenance.
“Ongoing translational research aims to better understand the mechanisms of responses to the study combination,” the study authors concluded.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.
JNCCN Spotlights
